Effect of melatonin supplementation in treatment of patients with polycystic ovary syndrome
Not Applicable
- Conditions
- Polycystic ovary syndrome.Polycystic ovarian syndromeE28.2
- Registration Number
- IRCT2017090533941N23
- Lead Sponsor
- Vice Chancellor for research of Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Patients with polycystic ovary syndrome aged 18 to 40 years
Exclusion Criteria
Pregnancy
Adrenal hyperplasia
Androgen-secreting tumors
Hyperprolactinemia
Thyroid dysfunction
Diabetes and other metabolic disorders at enrollment
Inflammatory and malignant diseases,
Taking melatonin supplements, antioxidant and/or anti-inflammatory supplements within 3 months prior to the enrollment
The night shift workers
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation using HOMA formula.
- Secondary Outcome Measures
Name Time Method